Public Sector Pension Investment Board maintained its stake in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) during the fourth quarter, Holdings Channel reports. The firm owned 25,000 shares of the company’s stock at the end of the fourth quarter. Public Sector Pension Investment Board owned approximately 0.05% of Amphastar Pharmaceuticals worth $461,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new stake in Amphastar Pharmaceuticals during the third quarter worth approximately $139,000. Atria Investments LLC bought a new stake in Amphastar Pharmaceuticals during the third quarter worth approximately $190,000. Princeton Alpha Management LP bought a new stake in Amphastar Pharmaceuticals during the third quarter worth approximately $195,000. Trexquant Investment LP bought a new stake in Amphastar Pharmaceuticals during the fourth quarter worth approximately $197,000. Finally, Smith Asset Management Group LP increased its stake in Amphastar Pharmaceuticals by 2.0% in the third quarter. Smith Asset Management Group LP now owns 11,990 shares of the company’s stock worth $227,000 after buying an additional 230 shares in the last quarter. Institutional investors and hedge funds own 49.09% of the company’s stock.

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) opened at 14.27 on Tuesday. The company has a market capitalization of $656.75 million, a P/E ratio of 64.86 and a beta of 1.74. The firm has a 50 day moving average price of $15.49 and a 200 day moving average price of $18.12. Amphastar Pharmaceuticals Inc has a one year low of $11.25 and a one year high of $21.75.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, March 13th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $63.54 million for the quarter, compared to analyst estimates of $55.78 million. Amphastar Pharmaceuticals had a return on equity of 6.79% and a net margin of 7.75%. Amphastar Pharmaceuticals’s quarterly revenue was down 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.19 EPS. On average, equities research analysts predict that Amphastar Pharmaceuticals Inc will post $0.40 EPS for the current fiscal year.

Your IP Address:

Several equities research analysts have issued reports on the company. BMO Capital Markets lowered their price target on Amphastar Pharmaceuticals from $18.00 to $16.00 and set a “market perform” rating for the company in a report on Tuesday, March 14th. Zacks Investment Research downgraded Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 4th. Piper Jaffray Companies lowered their price target on Amphastar Pharmaceuticals from $22.00 to $20.00 and set an “overweight” rating for the company in a report on Tuesday, March 14th. Needham & Company LLC lowered their price target on Amphastar Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 14th. Finally, Raymond James Financial, Inc. downgraded Amphastar Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and lowered their price target for the stock from $21.00 to $18.00 in a report on Tuesday, March 14th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $20.29.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

5 Day Chart for NASDAQ:AMPH

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH).

Receive News & Ratings for Amphastar Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.